12 January 2016: promotion of Zaluron XL by Fontus Health Ltd
Published 12 February 2016
© Crown copyright 2016
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-january-2016/12-january-2016-promotion-of-zaluron-xl-by-fontus-health-ltd
Aspire Pharma complained about a letter about Zaluron XL (quetiapine) sent to Cambridge and Peterborough CCGs by Fontus Health Ltd. The complainant alleged that the references for the material were incorrect and not up to date and the material was promotional but did not include the statutory information.
MHRA upheld the part of the complaint relating to provision of statutory information only. We considered that the material was promotional as it contained product claims and was aimed at persons qualified to prescribe or supply medicines and should therefore have included the statutory information. Fontus confirmed that they would ensure all promotional material included the statutory information. On the other points, Fontus confirmed that the references were up to date at the time of publishing the material and they held copies to support their claims.